Aptose Biosciences (NASDAQ:APTO) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a research note published on Tuesday,Benzinga reports. The brokerage currently has a $2.00 price target on the biotechnology company’s stock. Separately, StockNews.com initiated coverage on Aptose Biosciences in a research note on Saturday, December 7th. They set a […]

Leave a Reply

Your email address will not be published.

Previous post Financial Survey: Rubicon Technology (NASDAQ:RBCN) vs. VOXX International (NASDAQ:VOXX)
Next post Navigator (NYSE:NVGS) and Performance Shipping (NASDAQ:PSHG) Critical Review